SLC5A2 and diabetic ketoacidosis: This meta-analysis represents the most comprehensive evaluation to date of the risk of diabetic ketoacidosis (DKA) associated with SGLT2 inhibitors (SGLT2is), including the largest participant cohort ever analyzed for this purpose.